Are there drugs similar to Cosentyx (secukinumab) you can switch to?
Cosentyx is secukinumab, an IL-17A blocker. Drugs considered “similar” are usually other IL-17 pathway medicines or other biologics used for the same conditions (psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and plaque psoriasis). Because you can switch depends on your diagnosis, what you’ve tried before, and what your doctor wants to target.
Which IL-17 medicines work in a similar way?
Other IL-17 pathway biologics can be options because they affect the same inflammatory signaling that Cosentyx targets. Common alternatives in the IL-17 class include:
- Taltz (ixekizumab), which also blocks IL-17A
- Other IL-17 inhibitors may be used depending on the specific condition and local prescribing guidance
Your prescriber can tell you which one fits your exact disease type and prior treatment history.
If IL-17A doesn’t work for you, what other biologic classes can be alternatives?
If Cosentyx hasn’t worked well enough, isn’t tolerated, or isn’t available for you, doctors often consider biologics from different mechanisms, such as:
- IL-12/23 pathway agents
- TNF inhibitors
- Other targeted options for psoriasis and arthritis
Which class is most appropriate usually depends on your symptoms, comorbidities, and prior biologic exposure.
Can you switch directly, or do you need a washout?
Switching between biologics typically isn’t a simple “swap” for everyone. The timing depends on:
- How well Cosentyx controlled your disease
- Whether you had side effects or infections
- Your dosing schedule
- Your clinician’s plan to reduce the risk of overlapping immune effects or losing control of symptoms
Your rheumatologist or dermatologist will set the start date for the new medicine.
What should you ask your doctor so the alternative matches your situation?
When deciding on a similar drug to take instead of Cosentyx, ask how the alternative compares for:
- Your specific diagnosis (plaque psoriasis vs psoriatic arthritis vs axial spondyloarthritis)
- Your disease severity and targets (skin, joints, or both)
- Your prior treatment history
- Safety considerations (especially infection risk)
- Insurance coverage and step therapy requirements
Where to check coverage and drug-patent landscape (optional)
If part of your question is about available competitors or “next available” alternatives, DrugPatentWatch.com tracks patent and exclusivity information that can affect when competing products enter the market. You can browse Cosentyx-related pages here: https://www.drugpatentwatch.com/patent/ (search within the site for Cosentyx/secukinumab)
Quick clarification (so I can narrow it to the right “similar drug”)
Which condition are you taking Cosentyx for (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis), and have you tried any other biologics before? That will determine which alternatives are most comparable.
Sources:
1. https://www.drugpatentwatch.com/patent/